Literature DB >> 8569694

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.

A Schrattenholz1, E F Pereira, U Roth, K H Weber, E X Albuquerque, A Maelicke.   

Abstract

Similar to the gamma-aminobutyric acidA receptor and the N-methyl-D-aspartate subtype of glutamate receptor, neuronal nicotinic acetylcholine receptors are subject to positive modulatory control by allosterically acting ligands. Exogenous ligands such as galanthamine and the neurotransmitter 5-hydroxytryptamine, when applied in submicromolar concentrations with nicotinic agonists, significantly increase the frequency of opening of nicotinic receptor channels and potentiate agonist-activated currents. Because these effects have been shown to be blocked by the monoclonal antibody FK1, they are mediated by binding sites that are located on alpha subunits of nicotinic receptors and distinct from those for acetylcholine and acetylcholine-competitive ligands. At higher concentrations, the potentiating effect of these ligands decreases and is eventually overcome by an inhibition of the agonist-induced response. The sensitizing actions of galanthamine, 5-hydroxytryptamine, and related compounds, at submicromolar concentrations, may reflect the existence of cross-talk between adjacent neuroreceptors and synapses in the central nervous system and thus suggests the formation of transiently active chemical networks in the vertebrate brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8569694

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

3.  The effects of postnatal alcohol exposure and galantamine on the context pre-exposure facilitation effect and acetylcholine efflux using in vivo microdialysis.

Authors:  Amy E Perkins; Jim R Fadel; Sandra J Kelly
Journal:  Alcohol       Date:  2015-02-25       Impact factor: 2.405

4.  Activation of heteroliganded mouse muscle nicotinic receptors.

Authors:  Gustav Akk; Lorin S Milescu; Manfred Heckmann
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

5.  Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach.

Authors:  Bogdan Iorga; Denyse Herlem; Elvina Barré; Catherine Guillou
Journal:  J Mol Model       Date:  2005-12-22       Impact factor: 1.810

6.  Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome.

Authors:  Jing Zhao; Michael J Hylin; Nobuhide Kobori; Kimberly N Hood; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2017-12-18       Impact factor: 5.269

7.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

Review 8.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

9.  In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.

Authors:  Chandran Remya; Kalarickal Vijayan Dileep; Ignatius Tintu; Elessery Jayadevi Variyar; Chittalakkottu Sadasivan
Journal:  J Mol Model       Date:  2012-11-16       Impact factor: 1.810

10.  Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.

Authors:  Tse-Yu Wu; Caleb M Smith; Steven M Sine; Mark M Levandoski
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.